Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT02419937Not ApplicableCompleted

Short-Term Application of Tocilizumab Following Myocardial Infarction

Role: lead

NCT03190746Completed

Relationship of YWHAH Polymorphisms to Rheumatoid Arthritis Disease Severity

Role: lead

NCT02242630Not ApplicableCompleted

Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone to Improvement in Subacromial Bursitis

Role: lead

NCT01830725Completed

Purine Metabolism Enzyme SNP to Uric Acid Production

Role: lead

NCT01851902Unknown

PREdicting Atrial Fibrillation or Flutter

Role: lead

NCT01876329Completed

Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients

Role: lead

NCT01830699Not ApplicableCompleted

Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis

Role: lead

All 7 trials loaded